Pub. Date : 2021 Nov
PMID : 34596810
4 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Catalpol synergistically potentiates the anti-tumour effects of regorafenib against hepatocellular carcinoma via dual inhibition of PI3K/Akt/mTOR/NF-kappaB and VEGF/VEGFR2 signaling pathways. | regorafenib | vascular endothelial growth factor A | Homo sapiens |
| 2 | Novel therapies targeting these pathways have been discovered such as regorafenib which is small molecular multi-kinase inhibitor mainly targets VEGF/VEGFR2. | regorafenib | vascular endothelial growth factor A | Homo sapiens |
| 3 | In addition, results revealed that our novel combination of catalpol and regorafenib showed potent synergistic anti-tumour effect via suppressing both of PI3K/p-Akt/mTOR/NF-kappaB and VEGF/VEGFR2 signaling pathways and their downstreams. | regorafenib | vascular endothelial growth factor A | Homo sapiens |
| 4 | CONCLUSION: Catalpol and/or regorafenib markedly suppressed PI3K/p-Akt/mTOR/NF-kappaB and VEGF/VEGFR2 signaling pathways and consequently showed potent anti-tumour effects against HCC. | regorafenib | vascular endothelial growth factor A | Homo sapiens |